Forensic Genomics Firm Othram Raises $4M

Mar 12, 2019

|

NEW YORK (GenomeWeb) — Forensic genomics startup Othram said today that it has raised $4 million in Series A financing. Nimble Ventures, a San Francisco-based venture capital firm, led the round.

Othram said it has also been awarded a $10,000 research sequencing grant from Illumina Accelerator, Illumina's business incubator.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Up to Him

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

Study of Racism in Academic Research

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

Kodak Loan on Pause

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

Cell Studies on Blood Immune Features in Severe COVID-19 Cases, Alzheimer's Spatial Transcriptomes

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.

Featured White Papers

immunoSEQ Analyzer: Understanding Clonality

Compatibility of liquid biopsy assays on multiple sequencing platforms

Delivering Rapid Whole Genome Reports for ICU Cases with Opal Clinical STAT

White Paper: Using Single-Cell Multiomics to Reveal New Insights Into Uveal Melanoma Evolution and Therapeutic Resistance

Aug

18

Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

26

Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics.

Sep

01

Featured Webinar

Application of Whole-Exome Sequencing in Neurodevelopmental Disorders Research

This webinar will address the utility of exome sequencing for neurodevelopmental disorders research and will provide details of a comparison study of two exome probe kits in this field of study.

Menu

Forensic Genomics Firm Othram Raises $4M

To read the full story....

Breaking News

OpGen Q2 Revenues Climb 20 Percent

Biocept Q2 Revenues Down 23 Percent on Pandemic Impact

Traveler's Diarrhea Among Soldiers Linked to Gut Microbiome Changes

GeneCentric Therapeutics, Janssen Partner to Uncover Bladder Cancer Biomarkers

Pacific Biosciences Prices $86.9M Public Stock Offering

Personalis Prices $125M Public Stock Offering

The Scan

Up to Him

Study of Racism in Academic Research

Kodak Loan on Pause

Cell Studies on Blood Immune Features in Severe COVID-19 Cases, Alzheimer's Spatial Transcriptomes

Featured White Papers

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Utility of Novel RNA-Based Tools in Oncology Drug Development

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Application of Whole-Exome Sequencing in Neurodevelopmental Disorders Research

What's Popular?

Pacific Biosciences Prices $86.9M Public Stock Offering

NanoString Launches NGS Readout for Spatial Transcriptomics, Partners With Illumina on Informatics

10x Genomics Q2 Revenues Fall 23 Percent but Beat Wall Street Estimates

Personalis Prices $125M Public Stock Offering

Traveler's Diarrhea Among Soldiers Linked to Gut Microbiome Changes

Sponsorships